Minerva Neurosciences, Inc (NERV)

Last Price:  

Company Description

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company's pipeline will initially target the treatment of schizophrenia, major depressive disorder (MDD), insomnia, and Parkinson's disease. Its product candidates include MIN-101, MIN-117, MIN-202 and MIN-301. Minerva Neurosciences, Inc. is based in Cambridge, MA, United States.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) --
Net Income (Most Recent Fiscal Year) $-72.18M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 2.58
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -69.84%
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -66.72%
Return on Assets (Trailing 12 Months) -32.79%
Current Ratio (Most Recent Fiscal Quarter) 4.85
Quick Ratio (Most Recent Fiscal Quarter) 4.85
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $0.71
Earnings per Share (Most Recent Fiscal Quarter) $0.73
Earnings per Share (Most Recent Fiscal Year) $-1.85
Diluted Earnings per Share (Trailing 12 Months) $-0.71
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 41.21M
Free Float 34.78M
Market Capitalization $147.10M
Average Volume (Last 20 Days) 0.79M
Beta (Past 60 Months) 1.47
Percentage Held By Insiders (Latest Annual Proxy Report) 15.60%
Percentage Held By Institutions (Latest 13F Reports) 67.42%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%